Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Eudora
San Diego, California, United Stateseudragmp.ema.europa.eu ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Eudora is developing gene therapies for inherited retinal diseases using Replay's synHSV platform. The technology enables delivery of large or multiple genes not possible with AAV vectors. No clinical results have been reported as of May,2025[1][6][8][10].
- Therapeutic areas
- Rare DiseasesOphthalmology
- Modalities
- Gene therapy (HSV-1 vector)
- Industry
- Biotech
02
Partnerships
University of Pittsburgh technology license
Beyond the preview
Go deeper on Eudora.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Eudora.